Previous Article | Next Article 
Journal of Virology, December 2000, p. 10939-10949, Vol. 74, No. 23
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Region between Amino Acids 245 and 265 of the
Bovine Leukemia Virus (BLV) Tax Protein Restricts Transactivation Not
Only via the BLV Enhancer but Also via Other Retrovirus
Enhancers
Shigeru
Tajima and
Yoko
Aida*
RIKEN Tsukuba Institute, 3-1-1 Koyadai,
Tsukuba, Ibaraki 305-0074, Japan
Received 30 June 2000/Accepted 1 September 2000
 |
ABSTRACT |
Bovine leukemia virus (BLV) is associated with enzootic bovine
leukosis and is closely related to human T-cell leukemia virus type 1 (HTLV-1). The Tax protein of BLV acts through the 5' long terminal
repeat (LTR) of BLV and activates the transcription of BLV. In this
study, we amplified tax genes from BLV-infected cattle using PCR. We cloned the genes and monitored the transcriptional activities of the products. Seven independent mutant Tax proteins, with
at least one amino acid substitution between residues 240 and 265, exhibited a markedly stronger ability to stimulate the viral
LTR-directed transcription than the wild-type Tax protein. Analysis of
chimeric Tax proteins derived from wild-type and mutant Tax proteins
clearly demonstrated that a single substitution between residue 240 and
265 might be critical for the higher activities of the Tax mutant
proteins. Furthermore, it appeared that transient expression of a Tax
mutant protein was better able to increase the production of viral
proteins and particles from a defective recombinant proviral clone of
BLV than was wild-type Tax. Analysis of mutations within the U3 region
of the LTR revealed that a cyclic AMP-responsive element in
Tax-responsive element 2 might be sufficient for the enhanced
activation mediated by the mutant proteins. In addition to the LTR of
BLV, other viral enhancers, such as the enhancers of HTLV-1 and of
mouse mammary tumor virus, which cannot be activated by wild-type BLV
Tax protein, were activated by a Tax mutant protein. Our observations
suggest that the transactivation activity and target sequence
specificity of BLV Tax might be limited or negatively regulated
by the region of the protein between amino acids 240 and 265.
 |
INTRODUCTION |
Bovine leukemia virus (BLV) is the
etiologic agent of enzootic bovine leukosis (EBL), which is the most
common neoplastic disease of cattle, and it is often associated with
persistent lymphocytosis, which is characterized by an increased number
of normal B lymphocytes and the subsequent development of B-cell leukemia or lymphosarcoma after a long latency period (9). Sheep that are experimentally inoculated with BLV are readily infected,
and some develop B-cell tumors at higher frequencies and after a
shorter latency period than naturally inoculated cattle (3,
15). BLV is closely related to human T-cell leukemia virus type 1 (HTLV-1), which is the causative agents of adult T-cell leukemia and a
chronic neurological disorder known as tropical spastic paraparesis or
HTLV-1-associated myelopathy (10). BLV and HTLV constitute a
unique subgroup within the retrovirus family, being characterized by
similar genomic organizations, similar strategies for gene expression,
and similar pathologies. In addition to the structural proteins Gag,
Pol, and Env, these viruses encode at least two regulatory proteins,
namely, Tax and Rex, in the pX region located between the
env gene and the 3' long terminal repeat (LTR). The Tax
protein acts on a triplicate 21-bp motif known as the Tax-responsive
element (TxRE) in the U3 region of the 5' LTR, and it stimulates
transactivation of the virus genome (13, 16, 20, 52). The
TxRE consists of a cyclic AMP-response element (CRE)-like sequence, and
it has been suggested that Tax binds indirectly to this element through
cellular factors, such as members of the CREB/ATF family of
basic-leucine zipper proteins which have been shown to bind to the
CRE-like sequence (6, 43). The Tax protein of HTLV-1 is also
known to modulate the expression of many cellular genes that are
related to regulation of cell growth (61), but little is
known about the Tax protein of BLV (27). The Tax proteins of
BLV and HTLV-1 can cooperate with the Ha-Ras oncoprotein to induce the
full transformation of primary rat embryo fibroblasts (34,
54). These findings indicate that the Tax protein is a key
contributor to the oncogenic potential, as well as a key protein in the
replication of the virus. The Rex protein interacts with the
Rex-responsive element in the 3' R regions of the BLV and HTLV-1 mRNAs
and enhances the cytoplasmic accumulation of singly spliced and
unspliced transcripts. This enhancement leads to an increase in the
production of structural proteins and to a decrease in the level of the
doubly spliced tax-rex mRNA (14, 42).
RNA viruses have high rates of variation in nucleotide sequence, as
frequently observed in members of the lentivirus group, such as human
immunodeficiency virus (HIV), and such variation is important for viral
survival during immunological attack by the host's immune system.
However, in BLV and HTLV-1, the genetic variability appears to be
limited in vivo (12, 21, 57, 58). Moreover, it is difficult
to detect transcripts of the BLV and HTLV genomes in fresh tumor cells
or in fresh peripheral blood lymphocytes (PBL) from infected
individuals (18, 29). These findings suggest that the
BLV-HTLV subgroup might exploit a strict mechanism for control of the
expression of viral proteins throughout the course of leukemogenesis in
order to evade the host's immunosurveillance system. However, we do
not yet know how viral expression is inhibited in vivo. The increased
expression of BLV and HTLV-1 mRNAs can be induced by several activators
of lymphocytes, such as fetal calf serum, lipopolysaccharides, and
phorbol esters, after culture of lymphocytes in vitro (1, 24, 32,
33). Recent findings also indicate that interleukin-2 (IL-2)
activates BLV mRNA and enhances levels of viral proteins, while IL-10
inhibits detection of BLV mRNA (39). Furthermore,
phosphorylation of HTLV-1 Tax is critical for the transactivation
function of Tax, and the extent of such phosphorylation in human
lymphocytes is increased by treatment of cells with phorbol esters
(5, 17). We showed previously that BLV-infected cattle
retain a full-length proviral genome throughout the course of their
disease (44), in sharp contrast to the high frequencies (30 to 50%) of deletions in proviruses in HTLV-1-induced tumors (30,
37, 46). These findings suggest that a signal transduction
pathway that controls the activity of Tax in host cells, rather than
any genetic change in the BLV proviral genome, might play an important
role in regulating the activation and silencing of the virus.
In this study, we amplified tax genes from BLV-infected
animals using PCR, and then we cloned and sequenced the genes and identified seven independent Tax mutants, which were associated with
strikingly higher viral LTR-directed transcriptional activity than the
wild type. Furthermore, we found that amino acid substitutions between
amino acids 240 and 265 of Tax resulted in significantly increased
transactivational activity that involved a CRE motif in the BLV LTR.
Finally, we demonstrated that the mutant Tax protein also significantly
activated the 21-bp enhancer of HTLV-1 and the LTR of mouse mammary
tumor virus (MMTV) and was slightly effective with the LTRs of HIV type
1 (HIV-1) and of Moloney murine leukemia virus (M-MLV).
The mutant Tax proteins with elevated transactivation activity might
help us to elucidate the mechanism for strict regulation of the
expression of BLV.
 |
MATERIALS AND METHODS |
Amplification by PCR, cloning, and sequencing of the BLV
tax gene.
To amplify the BLV tax gene by
PCR, we used the oligonucleotide primers BtaxF
(5'-ACCTCGAGATGGCAAGTGTTGTTGGTTGG-3') and BtaxR (5'-AGTCTAGAGCTGACGTCTCTGTCTG-3'). The
underlined sequences are restriction sites specific for XhoI
and XbaI, respectively. Approximately 10 to 100 ng of
genomic or plasmid DNA was amplified in a 30-µl reaction mixture that
contained 1× EX Taq buffer (Takara Shuzo, Ohtsu, Japan) or
1× KOD-Plus buffer containing 1 mM MgSO4, (Toyobo, Kyoto,
Japan), 0.25 mM each deoxynucleoside triphosphate, 0.33 µM each
oligonucleotide primer, and 1 U of EX Taq (Takara Shuzo) or
KOD-PlusTM (Toyobo) DNA polymerase. Amplification was achieved by 35 cycles of incubation at 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min 30 s. To obtain Tax-expressing plasmids, PCR
products were introduced into the XhoI and XbaI
sites of the expression plasmid pME18Neo (45). Several
constructs were sequenced with a BigDye Terminator Cycle Sequencing Kit
and a Genetic Analyzer (ABI PRISM 310; PE Applied Biosystems, Norwalk,
Conn.) with the following primers: 7457R,
5'-GGGAACAACGTTCCATTGAG-3'; 7662R,
5'-GTTGTTCCAGGGAAGAAGGC-3'; 7855R,
5'-CTAGGGGTAGAATACAAGTAGC-3'; 8073R,
5'-CGTAGGGTCATGAAGAAGGAAGC-3'; and 8250R,
5'-CAGCTGACGTCTCTGTCTGGT-3'. To generate chimeric
Tax-expressing plasmids that encoded chimeric proteins Chi1 through
Chi4, we excised the XhoI-EcoRI fragment that
contained the sequence corresponding to amino acids 1 to 228 of the Tax
protein for Chi2 and Chi4 and the EcoRI-XbaI
fragment that contained the sequence corresponding to amino acids 229 to 309 of the Tax protein for Chi1 and Chi3 from the expression
plasmids that encoded the Tax mutants R73Q/V146I/S240T and A157V/T251A,
respectively. We then replaced the various sequences with the sequence
for an expression plasmid that encoded wild-type Tax.
Construction of plasmids.
To construct pGV-BLTR, we
amplified the full-length BLV LTR by PCR in 1× KOD-Plus buffer, 0.2 mM
each deoxynucleoside triphosphate, 1 mM MgSO4, and 1 U of
KOD-Plus DNA polymerase with primers (0.33 µM) BLTRF
(5'-TCCTGCAGTGTATGAAAGATCATGCCGAC-3') and BLTRR
(5'-AGTCTAGAATTGTTTGCCGGTCTCTC-3'), in which the
underlined sequences correspond to restriction sites for
PstI and XbaI, respectively, using the infectious
BLV molecular clone pBLV-IF (23) as template DNA. The PCR
product was treated with PstI, blunted with T4 DNA
polymerase, digested with XbaI, and then ligated into the
SmaI-NheI site of pGV(
), which is a plasmid
that corresponds to pGV-P (Toyo Ink, Tokyo, Japan) without the simian
virus 40 promoter sequence (BglII-HindIII
region). To generate pGV-BLTR
B, two oligonucleotides, namely,
BLTR
B1 (5'-TCGAGTGGCTAGAATCCCCGTACCTCCCCAACTTCCCCTTTCCCGAAAAATCCAC-3') and BLTR
B2
(5'-TCGAGTGGATTTTTCGGGAAAGGGGAAGTTGGGGAGGTACGGGGATTCTAGCCA-3'), in which the underlined sequences correspond to restriction sites for XhoI, were annealed and ligated at the XhoI
site of pGV-P. A clone with four copies of the oligonucleotide on the
sense strand was selected and used for luciferase assays. pGV-TxRE2 was
constructed by ligating an annealed oligonucleotide with TxRE2
sequences in the sense and antisense orientations
(5'-CTGAGCTGGTGACGGCAGCTGGTGGCGCCACCAGCTGCCGTCACCAGC-3'; the underlined sequence corresponds to a restriction site for XhoI) at the XhoI site of pGV-P. To generate
mutant reporter plasmids pGV-TxRE2m1 through pGV-TxRE2m5, we introduced
point mutations into pGV-TxRE2 by PCR-based site-directed mutagenesis,
as described previously (51), using KOD-Plus DNA polymerase
and the following oligonucleotide primers: m1,
5'-GCCACCAGCTGACGTCACCAGCTC-3'; m2,
5'-GCCACCAGCACCCGTCACCAGCTC-3'; m3,
5'-GCCTGCAGCTGCCGTCACCAGCTC-3'; m4,
5'-GCCACCAGCTGCGGTGACCAGCTC-3'; and
m5, 5'-GCCACGTGCTGCCGTCACCAGCTC-3' (bases
different from those in the wild-type sequence are shown in boldface).
For construction of pGV-HL21, the WT/BL plasmid (a kind gift from J. Fujisawa, Kansai Medical University, Osaka, Japan), which contains five
repeats of the HTLV-1 21-bp enhancer, was digested with
XhoI, blunted, and then digested with XbaI. The
fragment containing the 21-bp enhancers was ligated at the HindIII (blunted)-NheI sites of pGV-P. To
generate pGV-HIV-1 LTR(U3R), the U3-to-R region of the LTR of HIV-1 was
amplified by PCR as described above with primers HLF
(5'-TGGGGTACCTGGAAGGGCTAATTTGGTG-3'; the
underlined sequence corresponds to a restriction site for KpnI) and HLR
(5'-CCGCTCGAGTATTGAGGCTTAAGCAGT-3'; the
underlined sequence corresponds to a restriction site for
XhoI) and the HIV-1 plasmid pNL432 as the template. The PCR
product was subcloned into the KpnI-XhoI sites of
pGV(
). To construct pGV-MMTV LTR, we ligated the
BglII-HindIII fragment that contained the
full-length MMTV LTR from a hybrid MMTV provirus plasmid (kindly
donated by S. Yanagawa, Kyoto University, Kyoto, Japan) into the
BamHI-HindIII sites of pBluescript II SK(+)
(Stratagene, La Jolla, Calif.), and then the
XbaI-HindIII fragment containing the
full-length LTR of MMTV was subcloned into the
NheI-HindIII sites of pGV(
). For
construction of pGV-M-MLV LTR, the
EcoRI-HindIII fragment of the full-length LTR
of M-MLV, which had been cloned into pUC18 (a kind gift from A. Ishimoto, Kyoto University, Kyoto, Japan) was ligated into the
EcoRI-HindIII sites of pBluescript II SK(+) and the SpeI-HindIII fragment containing the
LTR of M-MLV was then subcloned into the
NheI-HindIII sites of pGV(
). To obtain the
HTLV-1 Tax-expressing plasmid pMEHtax, we subcloned the
EcoRI-BamHI fragment that contained the
tax sequence from pSGtax (a kind gift from M. Fujii, Niigata
University, Niigata, Japan), into pBluescript II SK(+), and then the
EcoRI-NotI fragment containing the tax sequence was subcloned into pME18Neo. The defective BLV infectious molecular clone pBLV-IFS240P was constructed by replacing
the ClaI-Eco47III fragment that included the
tax gene in pBLV-IF by the region of the mutant
tax clone that encoded S240P. pRL-SV40 (Promega, Madison,
Wis.) encodes a luciferase gene from Renilla and was used
for normalization of the efficiencies of transfections.
Cells, extraction of DNA, and transfections.
PBL were
separated from three BLV-infected but clinically and hematologically
normal cows, and total chromosomal DNA was extracted from these cells
as described previously (22). Tumor tissues were obtained
from three BLV-infected cows with lymphoma, and genomic DNA was
prepared from these tissues as described elsewhere (35).
293T cells, human embryonic kidney cells that express the large T
antigen of simian virus 40, were maintained in RPMI 1640 supplemented
with 10% heat-inactivated fetal calf serum.
For Western blotting, 293T cells (107) were transfected
with 10 µg of a Tax expression plasmid or a BLV molecular clone and 1 µg of pRL-SV40 by electroporation in a Gene Pulser (Bio-Rad, Hercules, Calif.) operated at 975 µF and 290 V. For analysis of luciferase activity, 293T cells (105/well) were transfected
with 1 µg of each reporter plasmid (which had an enhancer-promoter
sequence upstream of the firefly gene for luciferase), 0.5 µg of a
Tax-expressing plasmid, and 0.3 µg of pRL-SV40. Transfections were
performed with the DOSPER reagent (Roche Molecular Biochemicals,
Mannheim, Germany) as described previously (45).
Luciferase assay.
At 60 h after transfection, cells
were harvested and subjected to the assay for luciferase activity as
described elsewhere (45).
Western blotting analysis.
At 60 h after transfection,
cells were divided into two aliquots; one aliquot was used for
measurement of Renilla luciferase activity to monitor the
efficiency of transfection, and the other aliquot of cells was lysed
with lysis buffer (2% SDS and 2 mM phenylmethanesulfonyl fluoride plus
Complete Protease Inhibitor Cocktail [Roche Molecular Biochemicals]).
Proteins in lysates with equal Renilla luciferase activity
were examined by Western blotting analysis as described previously
(23). Virus particles were pelleted as described previously
(23) and subjected to Western blotting as described above.
We also examined the presence of Tax protein in cell lysates that were
used for luciferase assays by Western blotting with BLV Tax-specific B1
polyclonal antibodies (a kind gift from M. Sakurai, National Institute
of Animal Health, Tsukuba, Japan).
 |
RESULTS |
Ability of BLV Tax mutants to transactivate the BLV LTR.
To
clarify the way in which individual animals infected with BLV progress
from the asymptomatic stage to the disease stage, we investigated the
correlation between Tax activity and the progression of lymphoma. We
amplified tax genes from PBL and tumor tissues taken from
animals at the asymptomatic stage (A63, A69, and A78) and the lymphoma
stage (pr2170, pr2374, and pr2436), respectively, by PCR using EX
Taq polymerase. We subcloned the PCR products into the
mammalian cell expression vector pME18Neo. As a wild-type tax gene, a tax clone, IF-1, was similarly cloned
from an infectious molecular clone of BLV, pBLV-IF (Table
1) (23).
As shown in Fig.
1A and C, we obtained 91 and 97
tax clones from asymptomatic cattle and cattle with
EBL, respectively. All
188 clones were introduced into 293T cells with
the reporter plasmid
pGV-BLTR, which included the firefly gene for
luciferase driven
by a BLV LTR, and then we performed luciferase
analysis to compare
the transactivation activities of these clones
(Fig.
1). It was
clear that various Tax proteins were isolated from the
same individual
in all cases, and in addition, the clones could be
divided into
three groups depending on transactivation capacity. The
majority
(approximately 71%) of clones had activities similar to that
of
the wild-type
tax clone, irrespective of the stage of the
disease.
By contrast, some clones had higher or lower transactivation
activity
than the wild-type clone in the case of both the asymptomatic
and the lymphoma stages. There was no significant difference in
terms
of the rate of isolation of Tax mutant clones with high,
medium, and
low transactivation activities between healthy cattle
and those with
EBL (chi-square test, 0.1 <
P < 0.2).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 1.
Transactivation of the BLV LTR by various tax
clones from BLV-infected cattle. (A and B) BLV tax genes
were amplified by PCR with EX Taq (A) or KOD-Plus (B) DNA
polymerase from the genomic DNAs of BLV-infected animals and from a
molecular clone pBLV-IF and then subcloned into pME18Neo. 293T cells
were transfected with the reporter plasmid pGV-BLTR, the reference
plasmid pRL-SV40, and individual Tax-expressing plasmids. At 60 h
after transfection, cells were recovered and the activities of firefly
and Renilla luciferases were measured in lysates. For each
sample, the firefly luciferase activity (pGV-BLTR) was normalized by
reference to Renilla luciferase activity (pRL-SV40). The
extent of transactivation (fold) was calculated by dividing the
transactivation activity of the mutant Tax protein by that of wild-type
Tax protein. (C) Summary of the results shown in panels A and B. The
tax mutant clones were divided into three groups as follows,
with wild-type activity being taken as 1: high, >3-fold
transactivation; medium, 3- to 0.5-fold transactivation; low,
<0.5-fold transactivation.
|
|
We also amplified the
tax genes using KOD-Plus DNA
polymerase, which has considerably higher fidelity than EX
Taq polymerase
(Fig.
1B and C). No mutant Tax clones with
elevated transactivation
activity were isolated from two BLV-infected
animals and from
pBLV-IF, indicating that the mutations that we
identified were
a result of errors made by EX
Taq polymerase
during the amplification
of the
tax gene by
PCR.
Identification of the Tax mutants with elevated transactivation
activity.
We focused on the Tax mutant proteins with significantly
elevated transactivation activity in our effort to elucidate the mechanism that controls the activity of the Tax protein. We selected seven mutant tax clones with transactivation activity that
was 4- to 18-fold higher than that of the wild-type Tax clone, and we
determined the nucleotide sequences of these clones (Table 1). We first
determined the nucleotide sequence of the wild-type tax
clone IF-1 that we generated from the pBLV-IF provirus and compared it
with the sequences determined by Sagata et al. (
BLV-1) (40). Of the 930 bp of the full-length tax gene
that we sequenced, we identified only a single, silent point mutation
at codon 297. In the case of the seven mutant tax clones, we
found that each clone had at least one missense mutation between amino
acids 240 and 265, namely, at codon 240 (S
T), at codon 247 (D
G),
at codon 251 (T
A), at codon 258 (D
G), at codon 261 (H
R), at
codon 261 (H
Y), and at codon 265 (S
G). Among the seven clones,
only two clones (A63 28n [A157V/T251A] and pr2374 9 [R73Q/V146I/S240T]) also had missense mutations outside the region
that included amino acids 240 to 265 of the Tax protein, namely, at
codon 73 (R
Q), at codon 146 (V
I), and at codon 157 (A
V). The
positions and amino acids after the various substitutions differed
among the seven clones, with the exception of position 261 in clones
H261R and H261Y. In addition, we used one clone with weak
transactivation activity via the BLV LTR as a negative control in this
study; this clone had a missense mutation at codon 240 (S
P).
To analyze the correlation between the expression of and the ability to
activate the BLV LTR by the various Tax mutant proteins,
we transiently
transfected 293T cells with an expression vector
that encoded wild-type
Tax protein or a Tax mutant, together with
pGV-BLTR and pRL-SV40 for
normalization of the efficiency of transfection.
A fraction of each
cell lysate was used for analysis of expression
of the reporter gene,
and the remainder was used for detection
of Tax protein by Western
blotting with BLV Tax-specific polyclonal
antibodies (Fig.
2). Two Tax mutant proteins, namely,
R73Q/V146I/S240T
and S265G, were specifically expressed at levels
similar to that
of the wild-type Tax protein, while the levels of
expression of
the other five mutant proteins, namely, D258G,
A157V/T251A, H261R,
H261Y, and D247G, were lower than that of the
wild-type protein.
The Tax mutant with weak transactivation activity,
S240P, was
synthesized at a level similar to that of the wild-type Tax
protein.
Thus, there was no obvious relationship between
transactivation
activity and the level of expression of the Tax
protein, indicating
that the increase in transactivation activity was
due neither
to an increase in amount nor to enhanced stability due to
amino
acid substitution.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Transactivation activity and expression of Tax mutant
proteins. 293T cells were cotransfected with pME18Neo that encoded
wild-type or mutant Tax protein or with the control plasmid pME18Neo
together with pGV-BLTR and the reference plasmid pRL-SV40. At 60 h
after transfection, cells were taken for measurements of
Renilla luciferase activity. Lysates with equal
Renilla luciferase activity were subjected to firefly
luciferase assay (A) and Western blotting analysis (B). (A) Luciferase
activities were monitored and is presented as described in the legend
to Fig. 1. Each value represents the average obtained from two
independent transfection experiments. (B) To analyze the expression of
mutant Tax proteins, lysates were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis on a 10% polyacrylamide gel
and then analyzed by Western blotting with polyclonal antibodies (B1)
against BLV Tax. Similar results were obtained in two independent
experiments.
|
|
To evaluate whether only amino acid substitutions between amino acids
240 and 265 of the Tax protein might be involved in
the elevated
transactivation activity, we generated four chimeric
proteins (Chi1
through Chi4) by replacing sequences that encoded
each segment of
wild-type Tax protein by sequences that corresponded
to the
amino-terminal region from amino acids 1 through 228 or
to the
carboxy-terminal region from amino acids 229 through 309
of two Tax
mutants, R73Q/V146I/S240T and A157V/T251A. These Tax
mutants have amino
acid substitutions both beyond and between
residues 240 and 265, as
shown on the left in Fig.
3. Plasmids
encoding chimeric parental-mutant or wild-type Tax protein were
used to
cotransfect 293T cells together with pGV-BLTR, and then
transactivation
activities were examined (Fig.
3). The luciferase
activities of two
chimeric proteins, Chi1 (R73Q/V146I) and Chi3
(A157V), with missense
mutations outside residues 240 to 265 of
the Tax protein had only
approximately 10% of the activity of
each parental mutant, even though
they retained approximately
50% of the activity of the wild-type Tax
protein. By contrast,
the chimeras Chi2 (S240T) and Chi4 (T251A) each
retained most
of the transactivation activity of the respective
parental mutant.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
Transactivation of the BLV LTR by chimeric proteins
derived from wild-type and mutant Tax proteins. Plasmids expressing
chimeric proteins were created by replacing sequences that corresponded
to the amino-terminal regions or the carboxy-terminal regions of the
Tax mutants R73Q/V146I/S240T and A157V/T251A, with that of wild-type
Tax protein, as shown on the left. 293T cells were transfected with
pGV-BLTR, the reference plasmid pRL-SV40, and pME18Neo that encoded the
wild-type or chimeric Tax protein or with the control plasmid pME18Neo.
Luciferase activity was monitored and is presented as described in the
legend to Fig. 1. Each value represents the average obtained from two
independent transfection experiments. Asterisks indicate the positions
of missense mutations in each Tax protein.
|
|
These results demonstrated that with a single amino acid substitution,
such as S240T, D247G, T251A, D258G, H261R, H261Y, or
S265G, between
residues 240 and 265, the Tax protein of BLV is
endowed with
significantly increased ability to transactivate
the BLV LTR. However,
a loss-of-activity mutant of Tax, S240P,
also has a missense mutation
within this region. Thus, it is clear
that not only the position of the
missense mutation but also the
particular amino acid inserted as a
result might be an important
factor in Tax
activity.
A CRE, a cis element in TxRE2, is sufficient for the
enhanced activation of the BLV LTR by the mutant Tax proteins.
We
attempted to identify the regions in the BLV LTR that might be required
for the elevated transactivation activity. As shown in Fig.
4A, the U3 region of the BLV LTR contains
three imperfect direct repeats known as TxREs (TxRE1, TxRE2, and
TxRE3), which are critically important for the Tax-mediated activation
of the LTR. An NF-
B-binding site has also been identified between
TxRE2 and TxRE3 in the U3 region. It is associated with the strong
activation of transcription of BLV in the presence of NF-
B and Tax
in addition to a TxRE (7, 8).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 4.
Identification of the element in the BLV LTR that is
involved in the enhanced transactivation activity of Tax mutants
proteins. (A) Schematic illustration of the U3 region of the BLV LTR.
The upper boxes represent the locations of cis-acting
elements in the U3 region. The expanded region below the black box
shows the sites of site-directed mutagenesis in TxRE2 in the experiment
for which results are shown in panel C. The binding sites for
transcription factors CREB (CRE) and AP-4 are indicated by open boxes.
Bases different from the wild-type sequence are shown in boldface. The
consensus cellular CRE sequence is also indicated. (B) Transactivation
of the BLV LTR, TxRE2, and the NF- B-binding site in the U3 region by
Tax mutant proteins. The reporter plasmids (pGV-BLTR, pGV-TxRE2, and
pGV-BLTR B) were used for transfection together with pME18Neo that
encoded wild-type or mutant Tax protein or with the control plasmid
pME18Neo and the reference plasmid pRL-SV40. Luciferase activity was
monitored and is presented as described in the legend to Fig. 1. The
average values from two independent transfection experiments are shown.
(C) Transactivation of wild-type and mutant forms of TxRE2 by Tax
mutant proteins. The effector plasmid encoding wild-type Tax (bars 2, 6, 10, 14, 18, 22, 26, and 30), S240P (bars 3, 7, 11, 15, 19, 23, 27, and 31), or D247G (bars 4, 8, 12, 16, 20, 24, 28, and 32) or the
control plasmid pME18Neo (bars 1, 5, 9, 13, 17, 21, and 25) was used
for transfection together with the reporter plasmid that included the
BLV LTR (bars 5 to 8), TxRE2 (wild type) (bars 9 to 12), TxRE2m1 (bars
13 to 16), TxRE2m2 (bars 17 to 20), TxRE2m3 (bars 21 to 24), TxRE2m4
(bars 25 to 28), or TxRE2m5 (bars 29 to 32), or the control plasmid
pGV-P (bars 1 to 4), and the reference plasmid pRL-SV40. Luciferase
activity was measured as described in the legend to Fig. 1. The results
are presented as transactivation (fold) relative to the transactivation
activity resulting from transfection with pGV-P and pME18Neo (bar 1).
Average values from triplicate transfections with standard deviations
(error bars) are shown.
|
|
We constructed two reporter plasmids in which the TxRE2 (pGV-TxRE2) or
the NF-

B-binding site (pGV-BLTR

B) in the U3 region
of the BLV LTR
was linked to the upstream region of a luciferase
gene. We transfected
293T cells with these reporter plasmids together
with an expression
vector that encoded wild-type Tax protein or
a Tax mutant, or with the
control vector pME18Neo, and then we
monitored the transient expression
of luciferase (Fig.
4B). We
selected TxRE2 from among the three TxREs
because it appears that
TxRE2 is the most important element for the
Tax-driven activation
of the BLV LTR (
27). When we used
TxRE2 as an enhancer element,
the transactivating activities of the
seven independent Tax mutants
with elevated activity remained similar
to that observed with
the full-length LTR. By contrast, the wild-type
protein and four
Tax mutant proteins, A157V/Y251A, D258G, H261Y, and
S265G, failed
to activate the NF-

B-binding site, while the remaining
three
mutant proteins, R73Q/V146I/S240T, D247G, and H261R, only weakly
activated the NF-

B-binding site. The mutant protein S240P could
not
activate these enhancer sequences. Thus, it was clear that
the TxRE2
site was the main site involved in the increased transactivation
of BLV
LTR by the Tax mutant proteins. In subsequent experiments,
we used the
Tax mutant protein D247G because this protein had
the strongest
activity.
We next examined the target element of the Tax mutant in further
detail. TxRE2 consists of a CRE and a binding site for the
transcription factor AP-4. We introduced point mutations into
the CRE
(to yield TxRE2m1 and TxRE2m4), into AP-4 (TxRE2m5), into
the
overlapping region of the two motifs (TxRE2m2), and outside
the region
of both motifs (TxRE2m3) in the TxRE2 region of the
BLV LTR (Fig.
4A).
The various constructs were used to transfect
293T cells together with
an expression vector that encoded wild-type
Tax, D247G, or S240P or the
control vector pME18Neo, and then
we performed the luciferase assay
(Fig.
4C). In the presence of
D247G, the luciferase activity associated
with the
cis-element
mutants TxRE2m2 and TxRE2m3 was nearly
identical to that associated
with wild-type TxRE2, indicating that the
overlapping and outside
regions were not important in the increased
transactivation mediated
by the Tax mutant protein. By contrast, no
transactivation activity
was detected in cells transfected with all
constructs when pGV-TxRE2m4,
which has a disrupted CRE motif, was used
as the reporter plasmid.
TxRE2m1, which corresponded to the consensus
CRE sequence, yielded
elevated enhancer activity regardless of the
effector plasmids
used. The AP-4 mutant (TxRE2m5) was associated with
transactivation
activity at a level equivalent to approximately 50% of
that associated
with the wild-type TxRE2 but only in the presence of
the mutant
Tax protein
D247G.
Taken together, the results indicate that the CRE motif in TxRE2 might
be sufficient for the elevated transcription due to
the Tax mutant
proteins and that the AP-4 motif might play an
auxiliary role. We
failed to detect any transactivation activity
with wild-type Tax and
any variant of the TxRE2 sequence except
TxRE2m1. Thus, it appears that
wild-type Tax might need some other
motif(s) in the LTR in addition to
TxRE2.
Induction of the production of BLV structural proteins and virus
particles from the defective molecular clone pBLV-IFS240P
by the Tax mutant protein.
We next examined whether D247G could
induce the production of viral proteins and virus particles from the
defective recombinant provirus clone pBLV-IFS240P. The
defective clone of BLV was made by replacing the tax gene of
an infectious full-length molecular clone of BLV, pBLV-IF, by the gene
for the transactivation-negative Tax mutant S240P. The defective clone
was designated pBLV-IFS240P. As shown in Fig.
5, pBLV-IFS240P was unable to
synthesize viral proteins by itself, even though it retained all of the
normal viral genes apart from the tax sequence and the
entire LTR sequence.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 5.
Induction of the expression of viral structural proteins
and production of viral particles by Tax mutant proteins. A defective
molecular clone, pBLV-IFS240P, was used to cotransfect 293T
cells with a Tax-expressing plasmid that encoded wild-type (WT) Tax
protein (lane 2), S240P (lane 3), or D247G (lane 4), or with the
control plasmid pME18Neo (lane 1), and the reference plasmid pRL-SV40.
At 60 h after transfection, cell lysates (A) and concentrated
preparations of virus particles that had been released into the growth
medium (B) were subjected to Western blotting analysis with serum from
a BLV-infected sheep. The amounts of lysates and preparations of virus
particles subjected to electrophoresis were varied by reference to the
efficiency of transfection, which was assessed by monitoring
Renilla luciferase activity. Arrows on the right indicate
the positions of BLV structural proteins. Numbers on the left show
molecular masses.
|
|
We transiently transfected 293T cells with pBLV-IF
S240P,
together with an expression vector that encoded wild-type Tax protein,
D247G, or S240P or with the control vector, by electroporation
and then
analyzed the expression of BLV structural proteins by
Western blotting
with serum either from a BLV-infected sheep or
from a control sheep
(Fig.
5A). No detectable viral proteins were
found in cells that had
been cotransfected with pBLV-IF
S240P and either the control
plasmid or pME18Neo, which encoded the
Tax mutant protein S240P. By
contrast, bands corresponding to
the structural proteins of
cell-associated BLV, such as Gag and
its precursors (p24,
Pr45
Gag, and Pr70
Gag) and
Env and its precursors (gp30, gp51, and
gPr72
env), were detected specifically in cells
that had been cotransfected
with both pBLV-IF
S240P and an
expression plasmid that encoded wild-type Tax or D247G.
In the presence
of D247G, the levels of expression of viral structural
proteins from
pBLV-IF
S240P were much higher than those in the presence of
the wild-type
Tax
protein.
We also examined the BLV particles that had been released from the
cells (Fig.
5B). The intensities of the bands that corresponded
to the
structural protein in virions, such as p24, gp30,
Pr45
Gag, and gp51, obtained in the presence of
D247G were higher than
those obtained in the presence of the wild-type
construct. Moreover,
virus particles were not released from cells that
had been cotransfected
with pBLV-IF
S240P and either the
control plasmid or an expression plasmid that
encoded S240P. No
specific bands were detected in both types of
analysis with the control
serum from an uninfected sheep (data
not
shown).
Our results suggest that the specific amino acid substitutions between
amino acids 240 and 265 in the Tax protein of BLV result
in the
considerably increased ability of Tax to activate the production
of
virus particles of
BLV.
Tax mutant proteins with elevated transactivation activity also
activate other retrovirus enhancers.
It has been reported that BLV
Tax cannot activate the LTR of HTLV-1, which includes CRE motifs
(19). However, the results in Fig. 4C showed that D247G was
able to activate some modified CRE motifs, such as TxRE2m1 and TxRE2m2.
The sequences of these two CRE motif (TGACGTCA
and TGACGGGT) are more similar to that of
the CRE of HTLV-1 (TGACGTGT) than to that of wild-type TxRE2
(TGACGGCA) (the bases different from those in the sequence of the CRE of HTLV-1 are shown in boldface). Our observations suggested that a Tax mutant protein with elevated transactivation activity might be able to activate the HTLV-1 enhancer. To examine the
possibility, we cotransfected 293T cells with the reporter plasmid
pGV-HL21, which encodes five tandemly repeated 21-bp enhancers of
HTLV-1 that each contain a CRE motif, together with an effector plasmid
that encodes wild-type Tax, D247G, S240P, or HTLV-1 Tax or the control
vector pME18Neo, and then we analyzed the transactivation activity
(Fig. 6). D247G exhibited
considerable transactivation activity with the HTLV-1 enhancer,
even though it was only 30% as effective as HTLV-1 Tax. The mutant Tax
proteins H261R, R73Q/V146I/S240T, and A157V/T251A also have the ability
to transactivate the HTLV-1 enhancer (data not shown).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 6.
Transactivation of the enhancer sequences of various
retroviruses by Tax mutant proteins. The reporter plasmid pGV-P or
pGV( ) with HL21 (HTLV-1 enhancer) (bars 6 to 10), the HIV-1 LTR (U3R)
(bars 11 to 15), the MMTV LTR (bars 16 to 20), or the M-MLV LTR (bars
21 to 25), or the control plasmid pGV-P (bars 1 to 5), was used to
cotransfect 293T cells together with the effector plasmid that encoded
wild-type Tax protein (bars 2, 7, 12, 17, and 22), S240P (bars 3, 8, 13, 18, and 23), D247G (bars 4, 9, 14, 19, and 24), or HTLV-1 Tax
protein (bars 5, 10, 15, 20, and 25), or with the control plasmid
pME18Neo (bars 1, 6, 11, 16, and 21), and with the reference plasmid
pRL-SV40. Luciferase activity was monitored as described in the legend
to Fig. 1. The results are presented as the transactivation (fold)
relative to transactivation activity observed after cotransfection of
each reporter plasmid with the wild-type Tax-expressing plasmid.
Average results from triplicate transfections with standard deviations
(error bars) are shown.
|
|
We also examined the transactivation activity of D247G with three other
retroviral enhancers, namely, the LTRs of HIV-1, MMTV,
and M-MLV (Fig.
6). None of these three enhancers was activated
by wild-type BLV Tax.
D247G significantly transactivated the LTR
of MMTV (16-fold enhancement
of luciferase activity) and was slightly
effective with the other two
enhancers (2-fold enhancement of
leuciferase activity in each case). No
significant transactivation
of the MMTV and M-MLV enhancers was evident
in cells that expressed
HTLV-1 Tax. This result demonstrates the
possibility that mutants
of BLV Tax, such as D247G, might be able to
stimulate the expression
of viral genes that are not activated by the
wild-type Tax
protein.
 |
DISCUSSION |
In this study, we have identified several mutant BLV Tax proteins
that transactivated the LTR of BLV much more effectively than wild-type
Tax (Fig. 7). These mutant proteins
appeared to enhance the production of viral proteins and particles, as
compared to the wild-type Tax protein, via the LTR of a cotransfected
defective recombinant provirus clone of BLV. Nucleotide sequencing
demonstrated that each mutant protein had at least one missense
mutation between amino acids 240 and 265, namely, at codon 240, 247, 251, 258, 261, or 265, and some also had missense mutations outside
this region, namely, at codon 73, 146, or 157. Analysis with chimeric proteins generated from wild-type and mutant Tax proteins clearly demonstrated that a single substitution between residues 240 and 265 was critical for the elevated transactivation activities of the
Tax mutant proteins. The results of Western blotting analysis indicated
that the increased transactivation activities were due to qualitative
changes in the Tax protein and not to quantitative changes or
increased stability of the Tax protein. Moreover, we examined the
target of transactivation activity in detail and showed that a CRE
motif was sufficient for transactivation by the Tax mutant proteins via
the LTR of BLV. The mutant protein D247G also activated other
retrovirus enhancers, such as the 21-bp enhancers of HTLV-1 and the
LTRs of HIV-1, MMTV, and M-MLV, which were not activated by the
wild-type Tax from BLV. However, the CRE motif was not necessarily
essential for the activation of these retrovirus enhancers by the Tax
mutants, since no CRE motif is present in the LTRs of HIV-1, MMTV, and
M-MLV. Thus, our results suggest that a single substitution between
amino acids 240 and 265 not only stimulates the transactivation
activity of Tax protein but also increases the tolerance in terms of
specificity for target sequences in other LTRs.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 7.
Schematic representation of the BLV Tax protein. The
region between amino acids 240 and 265, in which missense mutations
influenced the transactivation activity of the Tax protein, is shown by
a black box. A putative zinc finger structure (dark-gray box; amino
acids 30 to 53), a leucine-rich activation domain (light-gray box;
amino acids 157 to 197), and sites of phosphorylation (amino acids 106 and 293) are also indicated.
|
|
Several Tax variants with activity markedly lower or higher than that
of wild-type Tax protein were identified in BLV-infected animals by PCR
with EX Taq polymerase. This result conflicts with previous
reports by Willems et al. (57, 58) of extremely low levels
of intrastrain variability among env genes and LTRs of BLV
in vivo. To confirm the existence of tax variants in cattle, we also amplified the tax genes with KOD-Plus DNA
polymerase, which has considerably higher fidelity than EX
Taq polymerase. In contrast, no mutant Tax clones with
elevated transactivation activity were identified from our BLV-infected
animals and from pBLV-IF. Therefore, the Tax variants we identified in
this study might not be seen in naturally BLV-infected cattle. However,
further studies are required to determine whether or not our mutations are attributable to errors made by EX Taq polymerase during PCR.
The enhanced activity of Tax mutant proteins might have been due to
alterations in the interaction between the Tax protein and cellular
factors as a result of the amino acid substitutions between amino acids
240 and 265. Binding of Tax protein to cellular factors has been
characterized in some detail, as follows. (i) HTLV-1 Tax protein cannot
bind directly to its target cis-acting elements, such as the
CRE motif and CArG box. However, it binds indirectly to these elements
via cellular transcription factors such as CREB, ATF, and SRF (19,
43, 50). Similar findings were also obtained in a functional
analysis of BLV Tax, but direct interactions of BLV Tax with specific
cellular transcription factors have not yet been demonstrated
(2). The BLV Tax mutant proteins with high transactivation
activity might bind more effectively to these transcription factors.
(ii) It has been reported that HTLV-1 Tax stimulates the binding of the
basic-leucine zipper domain, which had been found in many transcription
factors, including CREB and ATF, to the target motif of the Tax protein
by stabilizing dimerization of the factors and by altering the relative
affinity of the factors for different DNA-binding sites (4, 38,
50). It is possible that the mutations in Tax might lead to
enhancement of these biochemical functions of Tax. (iii) HTLV-1 Tax has
also been shown to interact with CREB-binding protein p300/CREB binding protein-associated factor (PCAF). These proteins are cellular coactivators with intrinsic histone acetyltransferase activity that
bind to various transcription factors such as CREB. Both CREB-binding
protein and PCAF are able to activate Tax-mediated transcription of
HTLV-1 (25, 26, 31). The Tax mutant proteins with higher
activity might have an enhanced ability to interact with these
coactivators, and consequently, they might increase the ability of
these coactivators and Tax to activate CRE-mediated transcription. (iv)
An unknown cellular factor(s) might interact with Tax and regulate its
function positively or negatively. Willems et al. (53, 55, 56,
59) performed a comprehensive analysis of the functional domains
of the BLV Tax protein, and they identified a putative zinc finger
motif (amino acids 30 to 53), a transactivating domain (amino acids 157 to 197), and two sites of phosphorylation (amino acids 106 and 293)
(Fig. 7). In addition, they also showed the possibility that the Tax
protein might be autoregulated by a region outside the transactivating
domain, the exact location of which remains to be determined
(55). The region between amino acids 240 and 265 of the Tax
protein might act as an negative regulatory domain, and missense
mutations in this region might enhance the transactivation activity of
Tax. Identification of the factor(s) that might interact with Tax
through amino acids 240 to 265 would help us to elucidate its role and
the mechanism that controls the activity of Tax protein.
Why is the transactivation activity of the wild-type Tax protein lower
than those of some of the Tax mutant proteins that we examined? The
majority of tax clones isolated in this study had activity
similar to that of wild-type tax irrespective of the
lymphoma stage. Thus, we may also ask why it is that host individuals
carry a great majority of BLV clones that encode Tax with only moderate
transactivation activity and not high activity. BLV Tax with strong
transactivation activity might be disadvantageous for the survival and
expansion of BLV, and hence, the optimum form of Tax might be the Tax
protein with transactivation activity suitable for both the induction
and the repression of the expression of BLV. BLV-infected animals
develop EBL after a long latency period. Moreover, during the latency
period, the expression of viral proteins appears to be blocked at the
transcriptional level (29, 32). This silencing is thought to
be very important for escape of BLV from the host's immunosurveillance
system. However, it is unknown how the expression of BLV is restricted
in vivo to levels that are undetectable by conventional methods.
Several candidate mechanisms for silencing have been proposed: (i)
accumulation and export of unspliced viral mRNA by Rex protein
(10), (ii) inactivation of a viral protein(s) caused by
mutation or deletion of the proviral genome (29, 36, 48,
49), (iii) blockage of the transcription of the viral LTR by DNA
methylation (11, 41), (iv) absence and/or inactivation of
cellular factors that can activate LTR-directed transcription (2,
24, 28, 39), and (v) induction and/or activation of cellular
factors that repress the viral transcription (39, 60).
Recently, Van Den Broeke et al. (49) reported that the
occurrence of a deficient Tax protein as a result of mutation may play
an important role in the silenced phenotype observed in BLV-induced
ovine B-cell tumors. However, the present results and previous findings
indicate that BLV-infected animals retain a full-length BLV proviral
genome, with functional tax and LTR sequences, throughout
the course of the disease (reference 44 and our
unpublished data). Furthermore, it appears that the extent of
variations in LTR and env sequences is very limited in
BLV-infected sheep (57). These results indicate that
silencing of a BLV provirus in vivo is not necessarily associated with
any deletion or mutation of the BLV proviral genome. Several lymphocyte
activators, such as fetal calf serum, lipopolysaccharides, IL-2, and
phorbol esters, can induce the expression of detectable amounts of
viral mRNA in lymphocytes from BLV- and HTLV-1-infected individuals
after culture in vitro (1, 24, 32, 33, 39). By contrast,
IL-10 reduces the level of expression of the viral mRNA
(39). Furthermore, phosphorylation of HTLV-1 Tax is critical for the transactivation function of Tax, and the phosphorylation of Tax
in human lymphocytes is increased by treatment of these cells with
phorbol esters (5, 17). Therefore, some signal transduction
pathways in the host cell might regulate the activity of Tax through
the region between amino acids 240 and 265 and, consequently, the
activation or silencing of BLV.
The Tax protein also appears to be critical to the oncogenic potential
of BLV and HTLV-1, and it induces the expression of many cellular
genes, including c-fos (47, 54, 61). Therefore, we must now clarify the role of Tax mutant proteins with elevated transactivation activity in BLV-induced leukemogenesis.
 |
ACKNOWLEDGMENTS |
We thank K. Okada (Iwate University, Iwate, Japan) for kindly
providing tumor tissue and peripheral blood from BLV-infected cattle
and M. Sakurai (National Institute of Animal Health, Tsukuba, Japan)
for Tax-specific antibodies. We also thank J. Fujisawa (Kansai Medical
School, Osaka, Japan), A. Ishimoto (Kyoto University, Kyoto, Japan), S. Yanagawa (Kyoto University), and M. Fujii (Niigata University, Niigata,
Japan) for kindly providing various plasmids.
This study was supported by Special Coordination Funds for the
Promotion of Science and Technology from the Science and Technology Agency of the Japanese Government, by grants from the Ministry and
Education, Science and Culture of Japan, by a President's Special
Research Grant from RIKEN, and by a grant for a special postdoctoral
researcher of RIKEN.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: RIKEN Tsukuba
Institute, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan. Phone:
81-298-36-3522. Fax: 81-298-36-9050. E-mail:
aida{at}rtc.riken.go.jp.
 |
REFERENCES |
| 1.
|
Adam, E.,
P. Kerkhofs,
M. Mammerickx,
R. Kettmann,
A. Burny,
L. Droogmans, and L. Willems.
1994.
Involvement of the cyclic AMP-responsive element binding protein in bovine leukemia virus expression in vivo.
J. Virol.
68:5845-5853[Abstract/Free Full Text].
|
| 2.
|
Adam, E.,
P. Kerkhofs,
M. Mammerickx,
A. Burny,
R. Kettman, and L. Willems.
1996.
The CREB, ATF-1, and ATF-2 transcription factors from bovine leukemia virus-infected B lymphocytes activate viral expression.
J. Virol.
70:1990-1999[Abstract].
|
| 3.
|
Aida, Y.,
M. Miyasaka,
K. Okada,
M. Onuma,
S. Kogure,
M. Suzuki,
P. Minoprio,
D. Levy, and Y. Ikawa.
1989.
Further phenotypic characterization of target cells for bovine leukemia virus experimental infection in sheep.
Am. J. Vet. Res.
50:1946-1951[Medline].
|
| 4.
|
Baranger, A. M.,
C. R. Palmer,
M. K. Hamm,
H. A. Giebler,
A. Brauweiler,
J. K. Nyborg, and A. Schepartz.
1995.
Mechanism of DNA-binding enhancement by the human T-cell leukaemia virus transactivator Tax.
Nature
376:606-608[CrossRef][Medline].
|
| 5.
|
Bex, F.,
K. Murphy,
R. Wattiez,
A. Burny, and R. Gaynor.
1999.
Phosphorylation of the human T-cell leukemia virus type 1 transactivator Tax on adjacent serine residues is critical for Tax activation.
J. Virol.
73:738-745[Abstract/Free Full Text].
|
| 6.
|
Boros, I. M.,
F. Tie, and C. Z. Giam.
1995.
Interaction of bovine leukemia virus transactivator Tax with bZip proteins.
Virology
214:207-214[CrossRef][Medline].
|
| 7.
|
Brooks, P. A.,
J. K. Nyborg, and G. L. Cockerell.
1995.
Identification of an NF-kappa B binding site in the bovine leukemia virus promoter.
J. Virol.
69:6005-6009[Abstract].
|
| 8.
|
Brooks, P. A.,
G. L. Cockerell, and J. K. Nyborg.
1998.
Activation of BLV transcription by NF-kappa B and Tax.
Virology
243:94-98[CrossRef][Medline].
|
| 9.
|
Burny, A.,
Y. Cleuter,
R. Kettmann,
M. Mammerickx,
G. Marbaix,
D. Portetelle,
A. van den Broeke,
L. Willems, and R. Thomas.
1988.
Bovine leukaemia: facts and hypotheses derived from the study of an infectious cancer.
Vet. Microbiol.
17:197-218[CrossRef][Medline].
|
| 10.
|
Cann, A. J., and I. S. Y. Chen.
1996.
Human T-cell leukemia virus types I and II, p. 1849-1880.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
|
| 11.
|
Cassens, S.,
U. Ulrich,
P. Beimling, and D. Simon.
1994.
Inhibition of human T cell leukaemia virus type I long terminal repeat expression by DNA methylation: implications for latency.
J. Gen. Virol.
75:3255-3259[Abstract/Free Full Text].
|
| 12.
|
Daenke, S.,
S. Nightingale,
J. K. Cruickshank, and C. R. Bangham.
1990.
Sequence variants of human T-cell lymphotropic virus type I from patients with tropical spastic paraparesis and adult T-cell leukemia do not distinguish neurological from leukemic isolates.
J. Virol.
64:1278-1282[Abstract/Free Full Text].
|
| 13.
|
Derse, D.
1987.
Bovine leukemia virus transcription is controlled by a virus-encoded trans-acting factor and by cis-acting response elements.
J. Virol.
61:2462-2471[Abstract/Free Full Text].
|
| 14.
|
Derse, D.
1988.
trans-acting regulation of bovine leukemia virus mRNA processing.
J. Virol.
62:1115-1119[Abstract/Free Full Text].
|
| 15.
|
Djilali, S.,
A. L. Parodi,
D. Levy, and G. L. Cockerell.
1987.
Development of leukemia and lymphosarcoma induced by bovine leukemia virus in sheep: a hematopathological study.
Leukemia
1:777-781[Medline].
|
| 16.
|
Felber, B. K.,
H. Paskalis,
C. Kleinman-Ewing,
F. Wong-Staal, and G. N. Pavlakis.
1985.
The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats.
Science
229:675-679[Abstract/Free Full Text].
|
| 17.
|
Fontes, J. D.,
J. M. Strawhecker,
N. D. Bills,
R. E. Lewis, and S. H. Hinrichs.
1993.
Phorbol esters modulate the phosphorylation of human T-cell leukemia virus type I Tax.
J. Virol.
67:4436-4441[Abstract/Free Full Text].
|
| 18.
|
Franchini, G.,
F. Wong-Staal, and R. C. Gallo.
1984.
Human T-cell leukemia virus (HTLV-I) transcripts in fresh and cultured cells of patients with adult T-cell leukemia.
Proc. Natl. Acad. Sci. USA
81:6207-6211[Abstract/Free Full Text].
|
| 19.
|
Fujii, M.,
H. Tsuchiya,
T. Chuhjo,
T. Minamino,
K. Miyamoto, and M. Seiki.
1994.
Serum response factor has functional roles both in indirect binding to the CArG box and in the transcriptional activation function of human T-cell leukemia virus type I Tax.
J. Virol.
68:7275-7283[Abstract/Free Full Text].
|
| 20.
|
Fujisawa, J.,
M. Seiki,
T. Kiyokawa, and M. Yoshida.
1985.
Functional activation of the long terminal repeat of human T-cell leukemia virus type I by a trans-acting factor.
Proc. Natl. Acad. Sci. USA
82:2277-2281[Abstract/Free Full Text].
|
| 21.
|
Gessain, A.,
R. C. Gallo, and G. Franchini.
1992.
Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations.
J. Virol.
66:2288-2295[Abstract/Free Full Text].
|
| 22.
|
Hughes, S. H.,
P. R. Shank,
D. H. Spector,
H. J. Kung,
J. M. Bishop,
H. E. Varmus,
P. K. Vogt, and M. L. Breitman.
1978.
Proviruses of avian sarcoma virus are terminally redundant, co-extensive with unintegrated linear DNA and integrated at many sites.
Cell
15:1397-1410[CrossRef][Medline].
|
| 23.
|
Inabe, K.,
K. Ikuta, and Y. Aida.
1998.
Transmission and propagation in cell culture of virus produced by cells transfected with an infectious molecular clone of bovine leukemia virus.
Virology
245:53-64[CrossRef][Medline].
|
| 24.
|
Jensen, W. A.,
B. J. Wicks-Beard, and G. L. Cockerell.
1992.
Inhibition of protein kinase C results in decreased expression of bovine leukemia virus.
J. Virol.
66:4427-4433[Abstract/Free Full Text].
|
| 25.
|
Jiang, H.,
H. Lu,
R. L. Schiltz,
C. A. Pise-Masison,
V. V. Ogryzko,
Y. Nakatani, and J. N. Brady.
1999.
PCAF interacts with Tax and stimulates Tax transactivation in a histone acetyltransferase-independent manner.
Mol. Cell. Biol.
19:8136-8145[Abstract/Free Full Text]. (Erratum 20:1897, 2000.)
|
| 26.
|
Kashanchi, F.,
J. F. Duvall,
R. P. Kwok,
J. R. Lundblad,
R. H. Goodman, and J. N. Brady.
1998.
The coactivator CBP stimulates human T-cell lymphotrophic virus type I Tax transactivation in vitro.
J. Biol. Chem.
273:34646-34652[Abstract/Free Full Text].
|
| 27.
|
Katoh, I.,
Y. Yoshinaka, and Y. Ikawa.
1989.
Bovine leukemia virus trans-activator p38tax activates heterologous promoters with a common sequence known as a cAMP-responsive element or the binding site of a cellular transcription factor ATF.
EMBO J.
8:497-503[Medline].
|
| 28.
|
Kerkhofs, P.,
E. Adam,
L. Droogmans,
D. Portetelle,
M. Mammerickx,
A. Burny,
R. Kettmann, and L. Willems.
1996.
Cellular pathways involved in the ex vivo expression of bovine leukemia virus.
J. Virol.
70:2170-2177[Abstract].
|
| 29.
|
Kettmann, R.,
J. Deschamps,
Y. Cleuter,
D. Couez,
A. Burny, and G. Marbaix.
1982.
Leukemogenesis by bovine leukemia virus: proviral DNA integration and lack of RNA expression of viral long terminal repeat and 3' proximate cellular sequences.
Proc. Natl. Acad. Sci. USA
79:2465-2469[Abstract/Free Full Text].
|
| 30.
|
Korber, B.,
A. Okayama,
R. Donnelly,
N. Tachibana, and M. Essex.
1991.
Polymerase chain reaction analysis of defective human T-cell leukemia virus type I proviral genomes in leukemic cells of patients with adult T-cell leukemia.
J. Virol.
65:5471-5476[Abstract/Free Full Text].
|
| 31.
|
Kwok, R. P.,
M. E. Laurance,
J. R. Lundblad,
P. S. Goldman,
H. Shih,
L. M. Connor,
S. J. Marriott, and R. H. Goodman.
1996.
Control of cAMP-regulated enhancers by the viral transactivator Tax through CREB and the co-activator CBP.
Nature
380:642-646[CrossRef][Medline].
|
| 32.
|
Lagarias, D. M., and K. Radke.
1989.
Transcriptional activation of bovine leukemia virus in blood cells from experimentally infected, asymptomatic sheep with latent infections.
J. Virol.
63:2099-2107[Abstract/Free Full Text].
|
| 33.
|
Lin, H. C.,
C. S. Dezzutti,
R. B. Lal, and A. B. Rabson.
1998.
Activation of human T-cell leukemia virus type 1 tax gene expression in chronically infected T cells.
J. Virol.
72:6264-6270[Abstract/Free Full Text].
|
| 34.
|
Matsumoto, K.,
H. Shibata,
J. I. Fujisawa,
H. Inoue,
A. Hakura,
T. Tsukahara, and M. Fujii.
1997.
Human T-cell leukemia virus type 1 Tax protein transforms rat fibroblasts via two distinct pathways.
J. Virol.
71:4445-4451[Abstract].
|
| 35.
|
McKnight, G. S.
1978.
The induction of ovalbumin and conalbumin mRNA by estrogen and progesterone in chick oviduct explant cultures.
Cell
14:403-413[CrossRef][Medline].
|
| 36.
|
Ogawa, Y.,
N. Sagata,
J. Tsuzuku-Kawamura,
H. Koyama,
M. Onuma,
H. Izawa, and Y. Ikawa.
1987.
Structure of a defective provirus of bovine leukemia virus.
Microbiol. Immunol.
31:1009-1015[Medline].
|
| 37.
|
Ohshima, K.,
M. Kikuchi,
Y. Masuda,
S. Kobari,
Y. Sumiyoshi,
F. Eguchi,
H. Mohtai,
T. Yoshida,
M. Takeshita, and N. Kimura.
1991.
Defective provirus form of human T-cell leukemia virus type I in adult T-cell leukemia/lymphoma: clinicopathological features.
Cancer Res.
51:4639-4642[Abstract/Free Full Text].
|
| 38.
|
Perini, G.,
S. Wagner, and M. R. Green.
1995.
Recognition of bZIP proteins by the human T-cell leukaemia virus transactivator Tax.
Nature
376:602-605[CrossRef][Medline].
|
| 39.
|
Pyeon, D., and G. A. Splitter.
1999.
Regulation of bovine leukemia virus tax and pol mRNA levels by interleukin-2 and -10.
J. Virol.
73:8427-8434[Abstract/Free Full Text].
|
| 40.
|
Sagata, N.,
T. Yasunaga,
J. Tsuzuku-Kawamura,
K. Ohishi,
Y. Ogawa, and Y. Ikawa.
1985.
Complete nucleotide sequence of the genome of bovine leukemia virus: its evolutionary relationship to other retroviruses.
Proc. Natl. Acad. Sci. USA
82:677-681[Abstract/Free Full Text].
|
| 41.
|
Saggioro, D.,
M. Forino, and L. Chieco-Bianchi.
1991.
Transcriptional block of HTLV-I LTR by sequence-specific methylation.
Virology
182:68-75[CrossRef][Medline].
|
| 42.
|
Seiki, M.,
J. Inoue,
M. Hidaka, and M. Yoshida.
1988.
Two cis-acting elements responsible for posttranscriptional trans-regulation of gene expression of human T-cell leukemia virus type I.
Proc. Natl. Acad. Sci. USA
85:7124-7128[Abstract/Free Full Text].
|
| 43.
|
Suzuki, T.,
J. I. Fujisawa,
M. Toita, and M. Yoshida.
1993.
The trans-activator tax of human T-cell leukemia virus type 1 (HTLV-1) interacts with cAMP-responsive element (CRE) binding and CRE modulator proteins that bind to the 21-base-pair enhancer of HTLV-1.
Proc. Natl. Acad. Sci. USA
90:610-614[Abstract/Free Full Text].
|
| 44.
|
Tajima, S.,
Y. Ikawa, and Y. Aida.
1998.
Complete bovine leukemia virus (BLV) provirus is conserved in BLV-infected cattle throughout the course of B-cell lymphosarcoma development.
J. Virol.
72:7569-7576[Abstract/Free Full Text].
|
| 45.
|
Tajima, S.,
W. Z. Zhuang,
M. V. Kato,
K. Okada,
Y. Ikawa, and Y. Aida.
1998.
Function and conformation of wild-type p53 protein are influenced by mutations in bovine leukemia virus-induced B-cell lymphosarcoma.
Virology
243:735-746[Medline].
|
| 46.
|
Tamiya, S.,
M. Matsuoka,
K. Etoh,
T. Watanabe,
S. Kamihira,
K. Yamaguchi, and K. Takatsuki.
1996.
Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia.
Blood
88:3065-3073[Abstract/Free Full Text].
|
| 47.
|
Tanaka, A.,
C. Takahashi,
S. Yamaoka,
T. Nosaka,
M. Maki, and M. Hatanaka.
1990.
Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro.
Proc. Natl. Acad. Sci. USA
87:1071-1075[Abstract/Free Full Text].
|
| 48.
|
Van den Broeke, A.,
Y. Cleuter,
G. Chen,
D. Portetelle,
M. Mammerickx,
D. Zagury,
M. Fouchard,
L. Coulombel,
R. Kettmann, and A. Burny.
1988.
Even transcriptionally competent proviruses are silent in bovine leukemia virus-induced sheep tumor cells.
Proc. Natl. Acad. Sci. USA
85:9263-9267[Abstract/Free Full Text].
|
| 49.
|
Van Den Broeke, A.,
C. Bagnis,
M. Ciesiolka,
Y. Cleuter,
H. Gelderblom,
P. Kerkhofs,
P. Griebel,
P. Mannoni, and A. Burny.
1999.
In vivo rescue of a silent Tax-deficient bovine leukemia virus from a tumor-derived ovine B-cell line by recombination with a retrovirally transduced wild-type tax gene.
J. Virol.
73:1054-1065[Abstract/Free Full Text].
|
| 50.
|
Wagner, S., and M. R. Green.
1993.
HTLV-I Tax protein stimulation of DNA binding of bZIP proteins by enhancing dimerization.
Science
262:395-399[Abstract/Free Full Text].
|
| 51.
|
Weiner, M. P.,
G. L. Costa,
W. Schoettlin,
J. Cline,
E. Mathur, and J. C. Bauer.
1994.
Site-directed mutagenesis of double-stranded DNA by the polymerase chain reaction.
Gene
151:119-123[CrossRef][Medline].
|
| 52.
|
Willems, L.,
A. Gegonne,
G. Chen,
A. Burny,
R. Kettmann, and J. Ghysdael.
1987.
The bovine leukemia virus p34 is a transactivator protein.
EMBO J.
6:3385-3389[Medline].
|
| 53.
|
Willems, L.,
G. Chen,
D. Portetelle,
R. Mamoun,
A. Burny, and R. Kettmann.
1989.
Structural and functional characterization of mutants of the bovine leukemia virus transactivator protein p34.
Virology
171:615-618[CrossRef][Medline].
|
| 54.
|
Willems, L.,
H. Heremans,
G. Chen,
D. Portetelle,
A. Billiau,
A. Burny, and R. Kettmann.
1990.
Cooperation between bovine leukaemia virus transactivator protein and Ha-ras oncogene product in cellular transformation.
EMBO J.
9:1577-1581[Medline].
|
| 55.
|
Willems, L.,
R. Kettmann, and A. Burny.
1991.
The amino acid (157-197) peptide segment of bovine leukemia virus p34tax encompass a leucine-rich globally neutral activation domain.
Oncogene
6:159-163[Medline].
|
| 56.
|
Willems, L.,
R. Kettmann,
G. Chen,
D. Portetelle,
A. Burny, and D. Derse.
1992.
A cyclic AMP-responsive DNA-binding protein (CREB2) is a cellular transactivator of the bovine leukemia virus long terminal repeat.
J. Virol.
66:766-772[Abstract/Free Full Text].
|
| 57.
|
Willems, L.,
E. Thienpont,
P. Kerkhofs,
A. Burny,
M. Mammerickx, and R. Kettmann.
1993.
Bovine leukemia virus, an animal model for the study of intrastrain variability.
J. Virol.
67:1086-1089[Abstract/Free Full Text].
|
| 58.
|
Willems, L.,
P. Kerkhofs,
A. Burny,
M. Mammerickx, and R. Kettmann.
1995.
Lack of LTR and ENV genetic variation during bovine leukemia virus-induced leukemogenesis.
Virology
206:769-772[CrossRef][Medline].
|
| 59.
|
Willems, L.,
C. Grimonpont,
P. Kerkhofs,
C. Capiau,
D. Gheysen,
K. Conrath,
R. Roussef,
R. Mamoun,
D. Portetelle,
A. Burny,
E. Adam,
L. Lefebvre,
J. C. Twizere,
H. Heremans, and R. Kettmann.
1998.
Phosphorylation of bovine leukemia virus Tax protein is required for in vitro transformation but not for transactivation.
Oncogene
16:2165-2176[CrossRef][Medline].
|
| 60.
|
Xiao, J., and G. C. Buehring.
1998.
In vivo protein binding and functional analysis of cis-acting elements in the U3 region of the bovine leukemia virus long terminal repeat.
J. Virol.
72:5994-6003[Abstract/Free Full Text].
|
| 61.
|
Yoshida, M.
1996.
Molecular biology of HTLV-I: recent progress.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
13:S63-S68.
|
Journal of Virology, December 2000, p. 10939-10949, Vol. 74, No. 23
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tajima, S., Tsukamoto, M., Aida, Y.
(2003). Latency of Viral Expression In Vivo Is Not Related to CpG Methylation in the U3 Region and Part of the R Region of the Long Terminal Repeat of Bovine Leukemia Virus. J. Virol.
77: 4423-4430
[Abstract]
[Full Text]
-
Tajima, S., Takahashi, M., Takeshima, S.-n., Konnai, S., Yin, S. A., Watarai, S., Tanaka, Y., Onuma, M., Okada, K., Aida, Y.
(2003). A Mutant Form of the Tax Protein of Bovine Leukemia Virus (BLV), with Enhanced Transactivation Activity, Increases Expression and Propagation of BLV In Vitro but Not In Vivo. J. Virol.
77: 1894-1903
[Abstract]
[Full Text]
-
Tajima, S., Aida, Y.
(2002). Mutant Tax Protein from Bovine Leukemia Virus with Enhanced Ability To Activate the Expression of c-fos. J. Virol.
76: 2557-2562
[Abstract]
[Full Text]
-
Merezak, C., Pierreux, C., Adam, E., Lemaigre, F., Rousseau, G. G., Calomme, C., Van Lint, C., Christophe, D., Kerkhofs, P., Burny, A., Kettmann, R., Willems, L.
(2001). Suboptimal Enhancer Sequences Are Required for Efficient Bovine Leukemia Virus Propagation In Vivo: Implications for Viral Latency. J. Virol.
75: 6977-6988
[Abstract]
[Full Text]